Anti-inflammatory strategies in the treatment of schizophrenia

Expert Review of Clinical Pharmacology

Volumn 9, Issue 2, 2016, Pages 161-163

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

anti inflammatory treatment; antipsychotic augmentation; aspirin; celecoxib; NSAIDs; schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; EPIGALLOCATECHIN GALLATE; MINOCYCLINE; NEUROSTEROID; OMEGA 3 FATTY ACID; ANTIINFLAMMATORY AGENT; NEUROLEPTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; ANIMAL; PATHOPHYSIOLOGY; PSYCHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; INFLAMMATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84958647209     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1095086     Document Type: Review

References (22)

1. Smyth AM, Lawrie SM. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci 2013;11:107-17
2. Feigenson KA, Kusnecov AW, Silverstein SM. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev 2014;38:72-93
3. Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014;75:292-9
4. Zakharyan R, Boyajyan A. Inflammatory cytokine network in schizophrenia. World J Biol Psychiatry 2014;15:174-87
5. Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophr Bull 2014;40:181-91
6. Nitta M, Kishimoto T, Muller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Schizophr Bull 2013;39: 1230-41
7. Weiser M, Burshtein S, Fodoreanu L, et al. A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffecive disorder. Neuropsychopharmacology 2012;38:S351
8. Laan W, Grobbee DE, Selten JP, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71:520-7
9. Lordkipanidze M. Advances in monitoring of aspirin therapy. Platelets 2012;23:526-36
10. Shader RI. Too good to be true Aspirin and schizophrenia. J Clin Psychopharmacol 2012;32:583-4
11. Rappard F, Muller N. Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia. Neuropsychopharmacology 2004;29:S222
12. Muller N, Riedel M, Dehning S, et al. Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology 2004;29:S176
13. Rapaport MH, Delrahim KK, Bresee CJ, et al. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005;57:1594-6
14. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-34
15. Muller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121:118-24
16. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90:179-85
17. Castellsague J, Riera-Guardia N, Calingaert B, et al. Safety of non-steroidal anti-inflammatory drugs (SOS) project. individual NSAIDs and upper gastrointestinal complications: A systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012;35:1127-46
18. De Vecchis R, Baldi C, Di Biase G, et al. Cardiovascular risk associated with celecoxib or etoricoxib: A meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol 2014;62:437-48
19. Andrade C. Nonsteroidal anti-inflammatory drugs and 5-HT3 serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia. J Clin Psychiatry 2014;75:e707-9
20. Loftis JM, Wilhelm CJ, Huckans M. Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: An 8-week, randomized, double-blind, placebo-controlled study. Ther Adv Psychopharmacol 2013;3:21-7
21. Keller WR, Kum LM, Wehring HJ, et al. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2013;27:337-42
22. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31-41